QUIDELORTHO CORP Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
QUIDELORTHO CORP (QDEL) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $4.90 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-07
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-28 was $4.90M, a 87.75% decline year-over-year.
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-29 was $11.30M, a 8.87% decline year-over-year.
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-28 was $4.30M.
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-28 was -$35.90M, a 270.14% decline year-over-year.
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $20.80M.
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$6.20M, a 116.49% decline from fiscal 2023.
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $37.60M.
- QUIDELORTHO CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$68.00M, a 8600.00% decline from fiscal 2022.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-28 | $4.90M 10-Q · filed 2026-08-07 | $16.20M 10-Q · filed 2026-08-07 | $20.50M derived: sum of 3 quarters · filed 2026-08-07 | -$15.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-29 | $11.30M 10-Q · filed 2026-08-07 | $15.60M derived: sum of 2 quarters · filed 2026-08-07 | -$20.30M derived: sum of 3 quarters · filed 2026-08-07 | $19.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-28 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$31.60M derived: sum of 2 quarters · filed 2026-02-19 | $8.40M derived: sum of 3 quarters · filed 2026-08-07 | $20.80M 10-K · filed 2026-02-19 |
| 2025-09-28 | -$35.90M 10-Q · filed 2025-11-06 | $4.10M derived: sum of 2 quarters · filed 2026-08-07 | $16.50M 10-Q · filed 2025-11-06 | -$16.20M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-29 | $40.00M 10-Q · filed 2026-08-07 | $52.40M 10-Q · filed 2026-08-07 | $19.70M derived: sum of 3 quarters · filed 2026-08-07 | $40.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-30 | $12.40M 10-Q · filed 2026-08-07 | -$20.30M derived: sum of 2 quarters · filed 2026-08-07 | $800.00K derived: sum of 3 quarters · filed 2026-08-07 | $2.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2024-12-29 | -$32.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$11.60M derived: sum of 2 quarters · filed 2026-02-19 | -$10.00M derived: sum of 3 quarters · filed 2026-02-19 | -$6.20M 10-K · filed 2026-02-19 |
| 2024-09-29 | $21.10M 10-Q · filed 2025-11-06 | $22.70M derived: sum of 2 quarters · filed 2025-11-06 | $26.50M 10-Q · filed 2025-11-06 | $49.70M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $1.60M 10-Q · filed 2025-08-06 | $5.40M 10-Q · filed 2025-08-06 | $28.60M derived: sum of 3 quarters · filed 2026-02-19 | -$8.30M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $3.80M 10-Q · filed 2025-05-08 | $27.00M derived: sum of 2 quarters · filed 2026-02-19 | -$9.90M derived: sum of 3 quarters · filed 2026-02-19 | $33.10M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $23.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$13.70M derived: sum of 2 quarters · filed 2026-02-19 | $29.30M derived: sum of 3 quarters · filed 2026-02-19 | $37.60M 10-K · filed 2026-02-19 |
| 2023-10-01 | -$36.90M 10-Q · filed 2024-11-08 | $6.10M derived: sum of 2 quarters · filed 2024-11-08 | $14.40M 10-Q · filed 2024-11-08 | $91.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | $43.00M 10-Q · filed 2024-08-01 | $51.30M 10-Q · filed 2024-08-01 | $128.20M derived: sum of 3 quarters · filed 2025-02-27 | $44.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | $8.30M 10-Q · filed 2024-05-09 | $85.20M derived: sum of 2 quarters · filed 2025-02-27 | $1.40M derived: sum of 3 quarters · filed 2025-02-27 | -$59.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-01-01 | $76.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$6.90M derived: sum of 2 quarters · filed 2025-02-27 | -$67.80M derived: sum of 3 quarters · filed 2025-02-27 | -$68.00M 10-K · filed 2025-02-27 |
| 2022-10-02 | -$83.80M 10-Q · filed 2023-11-02 | -$144.70M derived: sum of 2 quarters · filed 2023-11-02 | -$144.90M 10-Q · filed 2023-11-02 | |
| 2022-07-03 | -$60.90M 10-Q · filed 2023-08-09 | -$61.10M 10-Q · filed 2023-08-09 | ||
| 2022-01-02 | $800.00K 10-K/A · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |